英文播客:政策銀行的貪腐,艾伯維起訴製藥新星

陽歌 & 溫衛楠
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
And AbbVie has filed a suit in the U.S. against BeiGene, one of China’s most up-and-coming young drug makers. What’s likely to happen next in this tug of war between the two companies’ similar blood cancer drugs? Exactly how expensive and destructive are such lawsuits to the companies involved?
國開行成為反腐調查的目標,中國向發展中國家大量投放貸款的政策是否會因此調整?這背後的驅動力到底是什麼?
艾伯維在美國向百濟神州發起訴訟,後者是中國創新藥行業的佼佼者之一。這場白血病藥物專利大戰會走向何方?類似的官司到底會燒多少錢,產生多少破壞?
關於 China Inc
China Inc是咏竹坊製作的一系列播客節目,主要討論中概股的最新動態,幫助投資者了解這些公司以及它們所處的大環境,並根據相關資訊做出正確的決策。
您可以在這些平臺上找到我們的英文播客: